Tradestie Institutional Equity Comparison Engine

RGNX vs LXRX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RGNX Overall Edge

RGNX Captures Institutional Edge (3โ€“1 Pillars ยท 3โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to REGENXBIO Inc. (RGNX) driven by superior Valuation, Growth & Margin, Options & Structure while LXRX counters with relative strength in Momentum & Technical. Fundamentally, RGNX trades at N/M Forward P/E with -120.4% operating margin (-69.2% YoY revenue) versus LXRX at N/M Forward P/E and -147.4% operating margin (-20.7% YoY). In options structure, RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against LXRX sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner RGNX
RGNX N/M vs LXRX N/M Fwd P/E
Growth & Margin Winner RGNX
Op Margin -120.4% vs -147.4% ยท YoY -69.2% vs -20.7%
Momentum & Technical Winner LXRX
1Y -35.8% vs +21.2% ยท 52W Pos 19% vs 41%
Options & Structure Winner RGNX
BREAKDOWN (52nd %ile IV) vs BREAKDOWN (8th %ile IV)
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
1M Return +7.87%
1Y Return -35.82%
Forward P/E N/M
Unified AI Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
LXRX NASDAQ
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Preparations
$1.75
-2.51% 1D
Market Cap $810.3M
1M Return +14.8%
1Y Return +21.18%
Forward P/E N/M
Unified AI Score
38.7 / 100 SELL
Tech 5.0 Fund 33.0 Flow 65.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RGNX -35.82% LXRX +21.18% Spread: +57.0 pp (LXRX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RGNX Revenue LXRX Revenue RGNX Op. Margin LXRX Op. Margin Margin Edge
FY2018 $220M $30M 40.3% -388.5% RGNX
FY2019 $40M $30M -422.9% 437.5% LXRX
FY2020 $150M $20M -77.1% -204.2% RGNX
FY2021 $470M N/A 34.0% N/A RGNX
FY2022 $110M N/A -233.2% N/A RGNX
FY2023 $90M $0M -297.1% -15473.0% RGNX
FY2024 $80M $10M -280.0% -3284.7% RGNX
FY2025 $170M $50M -94.6% -98.2% RGNX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RGNX (3) vs LXRX (5)
Institutional Metric RGNX LXRX Criterion Row Winner
Market Capitalization Scale $500.9M $810.3M Larger Scale LXRX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -69.2% -20.7% Higher Growth LXRX
Operating Margin (TTM) Profitability -120.4% -147.4% Higher Margin RGNX
Net Profit Margin Profitability -113.9% -161.8% Higher Margin RGNX
Return on Equity (ROE) Capital Efficiency -113.2% -43.9% Higher ROE LXRX
52-Week Range Position Momentum 19% ($5โ€“$16) 41% ($1โ€“$3) Stronger Trend LXRX
Beta / 30D Volatility Risk Regime 1.81ฮฒ ยท 76% Vol 0.62ฮฒ ยท 60% Vol Lower Realized Risk LXRX
Unified Institutional Score Composite Signal 45.3 / 100 (HOLD) 38.7 / 100 (SELL) Higher Composite RGNX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RGNX vs LXRX Buy Guide
RGNX BREAKDOWN
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LXRX BREAKDOWN
98d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live LXRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RGNX nor LXRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.